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Abstract
Background and purpose: Previously it has been shown that patients with painful dia-
betic neuropathy (PDN) have greater corneal nerve loss compared to patients with pain-
less diabetic neuropathy. This study investigated if the severity of corneal nerve loss was 
related to the severity of PDN.
Methods: Participants with diabetic neuropathy (n = 118) and healthy controls (n = 38) 
underwent clinical and neurological evaluation, quantitative sensory testing, nerve con-
duction testing and corneal confocal microscopy and were categorized into those with no 
(n = 43), mild (n = 34) and moderate- to- severe (n = 41) neuropathic pain.
Results: Corneal nerve fibre density (p = 0.003), corneal nerve fibre length (p < 0.0001) 
and cold perception threshold (p < 0.0001) were lower and warm perception threshold 
was higher (p = 0.002) in patients with more severe pain, but there was no significant 
difference in the neuropathy disability score (p = 0.5), vibration perception threshold 
(p = 0.5), sural nerve conduction velocity (p = 0.3) and amplitude (p = 0.7), corneal nerve 
branch density (p = 0.06) and deep breathing heart rate variability (p = 0.08) between 
patients with differing severity of PDN. The visual analogue scale correlated significantly 
with corneal nerve fibre density (r = −0.3, p = 0.0002), corneal nerve branch density 
(r = −0.3, p = 0.001) and corneal nerve fibre length (r = −0.4, p < 0.0001). Receiver oper-
ating curve analysis showed that corneal nerve fibre density had an area under the curve 
of 0.78 with a sensitivity of 0.73 and specificity of 0.72 for the diagnosis of PDN.
Conclusions: Corneal confocal microscopy reveals increasing corneal nerve fibre loss 
with increasing severity of neuropathic pain and a good diagnostic outcome for identify-
ing patients with PDN.
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INTRODUC TION
Painful diabetic neuropathy (PDN) affects at least one in five adults 
with diabetes and has a major impact due to associated depression, 
anxiety and sleep disturbance [1]. Current therapies for PDN show 
limited efficacy [2] reflecting in part diverse aetiological mechanisms 
involving the peripheral nociceptor, spinal cord and brain [3]. It has 
been suggested that phenotyping patients and identifying the primary 
site and mechanism of their symptoms may allow a more tailored ther-
apeutic approach and improved response to treatment [4]. However, 
sensory testing, skin punch biopsy and brain imaging currently have in-
sufficient evidence to support their use as biomarkers in clinical trials 
of PDN [5] and an analysis of seven clinical trials utilizing sensory phe-
notyping showed a limited predictive impact on the efficacy of drugs 
used to relieve neuropathic pain [6].
A recent metanalysis has shown increased heat pain thresholds 
in patients with PDN compared to painless diabetic neuropathy [7]. 
However, a skin biopsy study showed no difference in intraepider-
mal nerve fibre density (IENFD) in patients with and without painful 
neuropathy [8]. In our previous study, whilst IENFD was comparable, 
there was a reduction in intraepidermal nerve fibre length (IENFL) in 
patients with PDN compared to painless diabetic neuropathy [9]. A 
study also found no difference in IENFD or axonal swellings between 
patients with PDN and painless diabetic neuropathy [10]. Additionally, 
another study found no difference in IENFD but an increase in the 
density of dermal nerve fibres containing substance P and calcitonin 
gene- related peptide in patients with PDN compared to painless di-
abetic neuropathy [11]. Bönhof et al. found comparable IENFD and 
IENFL, but increased dermal nerve GAP- 43 staining, indicative of re-
generating nerves in patients with PDN [12].
Corneal confocal microscopy (CCM) is a rapid, non- invasive technique 
that images C fibres in the cornea and has demonstrated good diagnos-
tic utility for diabetic neuropathy [13,14], comparable to IENFD [15,16]. 
Initially a significant reduction in corneal nerve fibre length (CNFL) was 
shown in a small cohort of patients with PDN compared to painless di-
abetic neuropathy [9]. Subsequently, a lower central and inferior whorl 
CNFL in patients with PDN was confirmed by ourselves and others 
[17,18]. Here it is investigated whether the severity of corneal nerve loss 
and other measures of neuropathy are related to the severity of PDN.
METHODOLOGY
Study participants
This study included 118 participants with diabetes (type 1, n = 45; 
type 2, n = 73) and 38 control subjects who underwent detailed as-
sessment of peripheral neuropathy and CCM. Participants were ex-
cluded if they had a history of connective tissue or infectious disease, 
malignancy, deficiency of B12 or folate, chronic renal or liver failure, 
current or active diabetic foot ulceration, previous ocular trauma, sys-
temic disease other than diabetes that involves the cornea, surgery 
and a history of or current contact lens wear. Informed consent was 
obtained from patients prior to study participation. The research ad-
hered to the tenets of the Declaration of Helsinki and was approved by 
the Greater Manchester East Research Ethics Committee.
Clinical and neuropathy assessment
A medical history was taken and body mass index, blood pressure, 
glycated haemoglobin (HbA1c) and lipid profile were evaluated. The 
neuropathy disability score (NDS) was used to assess vibration, pin-
prick sensation, temperature perception and the presence or absence 
of ankle reflexes. All patients had confirmed diabetic neuropathy 
based on an NDS > 2 [19]. All patients were asked not to use pain 
medications 24 h before the study assessments. The severity of pain at 
the study visit was recorded using a 0– 100 mm visual analogue scale 
(VAS). Patients were stratified into three groups according to pain 
severity: no pain (VAS 0– 4; n = 43), mild pain (VAS 5– 44; n = 34), 
moderate- to- severe pain (VAS 45– 100; n = 41) [20].
Deep breathing heart rate variability was assessed using the 
ANX 3.0 autonomic nervous system monitoring device (ANSAR 
Medical Technologies).
Vibration perception threshold (VPT) was assessed using a neu-
rothesiometer (Scientific Laboratory Supplies). Cold perception 
threshold (CPT) and warm perception threshold (WPT) were tested 
on the dorsolateral aspect of the non- dominant foot (S1) using a 
TSA- II NeuroSensory Analyser (Medoc Ltd). Electrodiagnostic studies 
were undertaken by a consultant neurophysiologist using a Dantec 
‘Keypoint’ system (Dantec Dynamics Ltd). Sural sensory nerve con-
duction velocity and amplitude were tested.
Ophthalmic assessment
Corneal sensitivity threshold was measured using a non- contact corneal 
aesthesiometer (Glasgow Caledonian University) [21]. CCM examination 
using a laser scanning corneal confocal microscope HRT III (Heidelberg 
Engineering) was performed for both eyes according to our established 
protocol [22]. Six images (three per eye) from the central sub- basal nerve 
plexus were selected by a single expert in a masked fashion, taking into 
account the quality, depth and variability according to our established 
protocol [23] and quantified manually using CCMetrics (University of 
Manchester). The corneal nerve fibre density (CNFD) (the total num-
ber of main nerves per square millimetre, no./mm2), the corneal nerve 
branch density (CNBD) (the total number of branches per square mil-
limetre, no./mm2) and the CNFL (the total length of main nerves and 
nerve branches per square millimetre, mm/mm2) were quantified.
Statistical analysis
Analysis was carried out using SPSS (Version 22.0 for Windows, 
IBM Corporation). The Shapiro– Wilk test was employed to assess 
whether the data were normally distributed. The non- parametric 
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Kruskal– Wallis H test was used to compare the differences between 
groups of patients whilst the Mann– Whitney U test was used for 
comparison between two groups. Data are expressed as median 
(range). For CCM parameters, data were adjusted for age and are 
presented as estimated marginal means ± SEM using ANCOVA (with 
least significant difference [LSD] correction). The ANCOVA (LSD) 
test was used to assess for differences between groups of patients. 
Spearman's rho correlation coefficient was used to assess associa-
tions between CCM parameters, other measures of neuropathy and 
the VAS score. Receiver operating characteristic (ROC) curves were 
used to define the optimum cut- off points with highest sensitivity 
and specificity for the diagnosis of PDN, and Youden's index, where 
J = sensitivity + specificity – 1, was used to measure the optimum 
cut- off points. Graphs were created using Graphpad Prism (Version 
7.0c for Windows, Graphpad Software).
RESULTS
Clinical and demographic assessment
Patients and healthy controls were matched for gender (p = 0.07). 
There was no significant difference in duration of diabetes 
(H(2) = 5.97, p = 0.051) between groups of patients (Table 1). 
Age (H(2) = 9.19, p = 0.01), type of diabetes (p < 0.0001), HbA1c 
(H(2) = 6.03, p = 0.05) and triglycerides (H(2) = 7.6, p = 0.02) differed 
significantly between groups of patients. The type of diabetes dif-
fered significantly between the patient groups with a significantly 
greater proportion of patients with type 2 diabetes in those with 
mild pain compared to comparable numbers with type 1 and type 2 
diabetes in those with moderate- to- severe pain (p = 0.002) and no 
pain (p = 0.003). HbA1c was significantly higher in patients with no 
(7.2 [7.4], p < 0.0001), mild (7.4 [4.3], p < 0.0001) and moderate- to- 
severe pain (8.1 [7.3], p < 0.0001) compared to controls (5.6 [1.3]) 
and in patients with moderate- to- severe pain compared to no pain 
(p = 0.03). Triglycerides were significantly lower in patients with no 
pain (1.10 [2.4]) compared to mild pain (1.65 [5.0], p = 0.007) and 
healthy controls (1.60 [4.3], p = 0.008). Low density lipoprotein cho-
lesterol was significantly lower in patients with mild pain (1.97 [3.6], 
p < 0.0001) compared to controls (2.84 [2.7]). 47.1% of patients with 
mild pain and 41.5% of patients with moderate- to- severe pain were 
on neuropathic pain relief medication.
Neuropathy assessment
Neuropathy disability score was significantly higher in diabetic pa-
tients with no pain (5 [7], p < 0.0001), mild pain (6 [7], p < 0.0001) 
and moderate- to- severe pain (6 [7], p < 0.0001) compared to con-
trols, but was comparable between the groups of patients with dif-
fering severity of neuropathic pain (H(2) = 1.2, p = 0.5) (Table 2). VPT 
was significantly higher in patients with no (21 [43], p < 0.0001), 
mild (21 [44.5], p < 0.0001) and moderate- to- severe pain (24 [44.5], 
p < 0.0001) compared to healthy controls (6 [23.75]) but was com-
parable between groups of patients with differing severity of neu-
ropathic pain (H(2) = 1.2, p = 0.5). Sural sensory nerve conduction 
velocity was significantly lower in patients with no (40.0 [18.9], 
p < 0.0001), mild (41.2 [26.6], p < 0.0001) and moderate- to- severe 
pain (40.0 [24.9], p < 0.0001) compared to healthy controls (50.0 
[20.9]) but did not differ between groups of patients with differing 
severity of neuropathic pain (H(2) = 1.98, p = 0.3). Sural nerve ac-
tion potential was significantly lower in patients with no (4.5 [25], 
TA B L E  1  Demographic and clinical data in controls and diabetic patients with no, mild and moderate- to- severe neuropathic pain
Controls n = 38 No pain n = 43 Mild pain n = 34
Moderate- to- severe 
pain n = 41 Kruskal– Wallis test
Age (years) 57 (36) 68 (47)a 68 (34)a 61 (50)b H(2) = 9.19, p = 0.01
Sex (female) 18 11 12 21 0.07c
Type of diabetes (T1DM/T2DM) 0 20/23 5/29 20/21 <0.0001c
Duration of diabetes (years) 0 16 (66) 15 (50) 24 (66)b H(2) = 5.97, p = 0.051
BMI (kg/m2) 26 (24) 29 (35) 32 (45)a 29 (18) H(2) = 4.46, p = 0.1
HbA1c (%) 5.6 (1.3) 7.2 (7.4)a 7.4 (4.3)a 8.1 (7.3)a,d H(2) = 6.03, p = 0.05
IFCC (mmol/mol) 37.35 (20.4) 55 (81.0)a 57 (46.0)a 65 (79.0)a,d H(2) = 5.9, p = 0.05
HDL- C (mmol/l) 1.53 (1.72) 1.38 (2.32) 1.33 (2.10) 1.44 (2.78) H(2) = 2.1, p = 0.3
Triglycerides (mmol/l) 1.60 (4.3) 1.10 (2.4)a 1.65 (5.0)d 1.40 (3.6) H(2) = 7.6, p = 0.02
LDL- C (mmol/l) 2.84 (2.7) 1.63 (2.62) 1.97 (3.6)a 1.86 (2.9) H(2) = 2.6, p = 0.2
Note: Kruskal– Wallis test is performed between groups of patients. All data are presented as median (range).
Abbreviations: BMI, body mass index; HDL- C, high density lipoprotein cholesterol; IFCC, International Federation of Clinical Chemistry; LDL- C, low 
density lipoprotein cholesterol; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
aSignificant difference compared to controls.
bSignificant difference compared to mild pain.
cp value refers to Fisher's exact test.
dSignificant difference compared to no pain.
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p < 0.0001), mild (5.35 [17], p < 0.0001) and moderate- to- severe 
pain (4.2 [26], p < 0.0001) compared to healthy controls (16.0 [37.4]) 
but did not differ between groups of patients with differing sever-
ity of neuropathic pain (H(2) = 0.6, p = 0.7). CPT was significantly 
lower in patients with no (26.1 [31.6], p < 0.0001), mild (25.25 [30.3], 
p = 0.004) and moderate- to- severe pain (22.1 [29], p < 0.0001) com-
pared to controls (27.9 [12.9]) and was significantly lower in patients 
with moderate- to- severe pain compared to no (p < 0.0001) and mild 
TA B L E  2  Neuropathy testing in controls and diabetic patients with no, mild and moderate- to- severe neuropathic pain
Controls n = 38 No pain n = 43 Mild pain n = 34
Moderate- to- severe 
pain n = 41 Kruskal– Wallis test
NDS (0– 10) 0 (6) 5 (7)a 6 (7)a 6 (7)a H(2) = 1.2, p = 0.5
DB- HRV (beats per min) 16 (5) 15 (41) 13 (38) 9 (56)a H(2) = 4.9, p = 0.08
VPT (V) 6 (23.75) 21 (43)a 21 (44.5)a 24 (44.5)a H(2) = 1.2, p = 0.5
CPT foot (°C) 27.9 (12.9) 26.1 (31.6)a 25.25 (30.3)a 22.1 (29)a,b,c H(2) = 15.4, p < 0.0001
WPT foot (°C) 38.5 (19.1) 41.0 (16.6)a 42.1 (16.1)a 44.8 (15.2)a,b H(2) = 12.17, p = 0.002
SNCV (m/s) 50.0 (20.9) 40.0 (18.9)a 41.2 (26.6)a 40.0 (24.9)a H(2) = 1.98, p = 0.3
SNAP (mV) 16.0 (37.4) 4.5 (25.0)a 5.35 (17.0)a 4.2 (26.0)a H(2) = 0.6, p = 0.7
Note: Data presented as median (range). p value less than 0.01 was considered as significant. Kruskal– Wallis test is performed between groups of 
patients.
Abbreviations: CPT, cold perception threshold; DB- HRV, deep breathing heart rate variability; NDS, neuropathy disability score; SNAP, sural nerve 
action potential; SNCV, sural nerve conduction velocity; VPT, vibration perception threshold; WPT, warm perception threshold.
aSignificant difference compared to controls.
bSignificant difference compared to no pain.
cSignificant difference compared to mild pain.
TA B L E  3  Corneal sensitivity and confocal microscopy parameters in controls and diabetic patients with no, mild and moderate- to- severe 
pain
Controls n = 38 No pain n = 43 Mild pain n = 34
Moderate- to- severe pain 
n = 41 ANCOVA
NCCA (mbar) 0.6 ± 0.19 0.89 ± 0.20 0.65 ± 0.24 1.63 ± 0.24b,c F(2, 113) = 4.2, p = 0.007
CNFD (no./mm2) 33.56 ± 1.25 23.67 ± 1.15c 20.85 ± 1.29c  17.27 ± 1.18b,c F(2, 113) = 6.3, p = 0.003
CNBD (no./mm2) 92.75 ± 5.09 56.47 ± 4.56c 45.20 ± 5.14c 40.60 ± 4.71c F(2, 113) = 2.9, p = 0.06
CNFL (mm/mm2) 27.06 ± 1.13 22.47 ± 1.03c 20.21 ± 1.17c 15.82 ± 1.07b,c F(2, 113) = 8.18, p < 0.0001
Note: Data are adjusted for age and presented as estimated marginal means ± SEM using ANCOVA (LSD correction). The ANCOVA (LSD correction) 
test is done between groups of patients.
Abbreviations: CNBD, corneal nerve branch density; CNFD, corneal nerve fibre density; CNFL, corneal nerve fibre length; NCCA, non- contact 
corneal aesthesiometer.
aSignificant compared to no pain.
bSignificant difference compared to mild pain.
cSignificant difference compared to controls.
F I G U R E  1  CCM images of a healthy control (a) and age- matched patients with no (b), mild (c) and moderate- to- severe (d) neuropathic pain
(a) (b) (c) (d)
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(p = 0.009) pain. WPT was significantly higher in patients with no 
(41.0 [16.6], p = 0.01), mild (42.1 [16.1], p < 0.0001) and moderate- 
to- severe pain (44.8 [15.2], p < 0.0001) compared to controls (38.5 
[19.1]) and was higher in patients with moderate- to- severe pain com-
pared to no pain (p = 0.002). CPT and WPT differed significantly be-
tween groups of patients (H(2) = 15.4, p < 0.0001; and H(2) = 12.17, 
p = 0.002). Deep breathing heart rate variability was significantly 
lower only in patients with moderate- to- severe pain compared to 
controls (p = 0.03) and did not differ significantly between groups of 
patients (H(2) = 4.9, p = 0.08).
Corneal assessment
Corneal sensitivity threshold was significantly higher in the group 
with moderate- to- severe pain (1.63 ± 0.24) compared to controls 
(0.6 ± 0.19, p = 0.001), no pain (0.89 ± 0.20, p = 0.02) and mild 
pain (0.65 ± 0.24, p = 0.005). The CNFD was significantly lower 
in patients with no (23.67 ± 1.15, p < 0.0001), mild (20.85 ± 1.29, 
p < 0.0001) and moderate- to- severe (17.27 ± 1.18, p < 0.0001) 
pain compared to controls (Table 3, Figures 1 and 2) and in patients 
with moderate- to- severe pain compared to no pain (p < 0.0001) 
and mild pain (p = 0.01). CNBD was significantly lower in patients 
with no (56.47 ± 4.56, p < 0.0001), mild (45.20 ± 5.14, p < 0.0001) 
and moderate- to- severe (40.60 ± 4.71, p < 0.0001) pain com-
pared to controls and in moderate- to- severe pain (p = 0.02) com-
pared to no pain. CNFL was lower in no (22.47 ± 1.03, p = 0.004), 
mild (20.21 ± 1.17, p < 0.0001) and moderate- to- severe pain 
(15.82 ± 1.07, p < 0.0001) compared to controls and was lower in 
moderate- to- severe pain compared to mild pain (p = 0.007) and 
no pain (p < 0.0001). There was a significant difference in cor-
neal sensitivity (F(2, 113) = 4.2, p = 0.007), CNFD (F(2, 113) = 6.3, 
p = 0.003) and CNFL (F(2, 113) = 8.18, p < 0.0001) but no dif-
ference in CNBD (F(2, 113) = 2.9, p = 0.06) between groups of 
patients.
Association between VAS, CCM and other 
measures of neuropathy
Visual analogue scale correlated significantly with CNFD (r = −0.3, 
p = 0.0002), CNBD (r = −0.3, p = 0.001) and CNFL (r = −0.4, 
p < 0.0001) (Figure 3) and with WPT (r = 0.3, p = 0.0004) and CPT 
(r = −0.35, p = 0.0001). There was no correlation between VAS and 
measures of large fibre neuropathy. Corneal sensitivity threshold 
was significantly associated with CNFD (r = −0.4, p = 0.005).
Diagnostic utility of CCM for PDN
For the diagnosis of PDN (VAS > 4 and NDS > 2) ROC curve analysis 
revealed an area under the curve (AUC) for CNFD of 0.78 with a 
sensitivity of 0.73, specificity of 0.72 and optimal threshold of 23.69 
(no./mm2) (Figure 4, Table 4). CNBD had an AUC of 0.75 with sensi-
tivity of 0.66, specificity of 0.66 and an optimal threshold of 51.04 
(no./mm2). CNFL had an AUC of 0.74 with a sensitivity of 0.66 and 
specificity of 0.65 and an optimal threshold of 21.48 (mm/mm2).
DISCUSSION
In the current study, greater small nerve fibre dysfunction and dam-
age was evidenced by increased cold and warm thermal thresholds 
and greater corneal nerve loss, respectively, with increasing sever-
ity of PDN. The aetiology of PDN is complex with a contribution 
of genetics, gender, glycaemic control peripheral nerve, spinal cord 
and brain pathology [24,25]. However, there is an increasing body of 
evidence for the permissive role of peripheral small nerve fibre dys-
function and damage in the development and maintenance of PDN 
[4,9,17,26].
Benbow et al. (1994) followed 50 patients with PDN over 
3.6 years and found no association between the initial or follow- up 
F I G U R E  2  Corneal nerve fibre parameters as dot plots and mean ± SD for controls and patients with no, mild and moderate- to- severe 
pain: (a) corneal nerve fibre density; (b) corneal nerve branch density; (c) corneal nerve fibre length
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pain scores and a range of measures of small fibre function including 
thermal limen, heat pain threshold and weighted pinprick thresh-
old [27]. However, recently two large cross- sectional cohort stud-
ies have reported an association between thermal sensory loss and 
neuropathic pain [28,29]. There is debate regarding the association 
between alterations in intraepidermal nerve fibre morphology and 
the severity or characteristics of PDN. Thus, whilst some studies 
of patients with PDN have shown intraepidermal nerve fibre loss 
[12,30], others have not [10,12,31,32]. Furthermore, other recent 
studies have shown comparable IENFD but increased dermal nerve 
fibres in PDN compared to painless diabetic neuropathy [11,12].
Corneal nerve fibre damage has been reported by ourselves 
and others in adults with diabetic peripheral neuropathy [33] 
children with type 1 diabetes without neuropathy [34], adults 
with type 1 diabetes without overt microvascular complications 
[35], subjects with impaired glucose tolerance [36] and recently 
diagnosed patients with type 2 diabetes [37]. However, patients 
with PDN have greater corneal nerve loss compared to patients 
with painless diabetic neuropathy [9,17,26,38,39]. Furthermore, 
greater corneal nerve loss has been shown in patients with more 
painful symptoms [38]. Further support for the relationship be-
tween the severity of corneal nerve loss and neuropathic pain is 
now provided, by showing a greater reduction in CNFD and length 
in patients with more severe PDN and a significant correlation be-
tween the severity of PDN and corneal nerve fibre loss [38]. CNBD 
did not differ significantly between patients with differing severity 
of PDN and may reflect concomitant small fibre degeneration and 
regeneration. Indeed, Püttgen et al. (2019) also recently reported 
increased CNBD, indicative of small nerve fibre regeneration in 
patients with PDN [40]. Significantly lower corneal sensitivity has 
been shown previously in patients with PDN compared to pain-
less diabetic neuropathy [39]. In the current study, lower corneal 
F I G U R E  3  Association plots between 
VAS and measures of small and large fibre 
neuropathy
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sensitivity is also reported in patients with moderate- to- severe 
pain compared to those with mild or no pain.
Deep breathing heart rate variability, a marker of cardiac au-
tonomic dysfunction, was also lower in patients with moderate- 
to- severe PDN, which is consistent with a previous study showing 
greater autonomic dysfunction in patients with PDN [41]. The re-
lationship between PDN and autonomic dysfunction may indicate 
an effect on cutaneous blood flow as impaired cutaneous sympa-
thetic vasoconstriction has been shown previously in patients with 
PDN [42].
It is important to note that the associations observed do not sim-
ply reflect more severe neuropathy in those with more severe PDN 
as there was no difference in the NDS, VPT and sural nerve conduc-
tion and amplitude between patients with differing severity of PDN. 
These findings are consistent with our recent studies where signifi-
cantly greater small nerve fibre damage was demonstrated but there 
was no difference in measures of large fibre neuropathy between 
patients with PDN compared to painless diabetic peripheral neurop-
athy [17,38]. Several other studies have also shown no difference 
in measures of large fibre dysfunction or damage between patients 
with PDN and painless diabetic neuropathy [40]. Krämer et al. found 
no difference in nerve conduction studies [NCS] and VPT between 
patients with PDN and painless diabetic neuropathy; however, in the 
PDN group there was a correlation between pain intensity ratings 
and the cold detection threshold [43]. Spallone et al. have demon-
strated a significant correlation between the 24- h average pain score 
with the Michigan diabetic neuropathy score and Valsalva ratio [44].
Several previous studies have shown that CCM has a good diag-
nostic accuracy for diabetic peripheral neuropathy [13,14]. This is 
the first study to demonstrate good diagnostic accuracy for all three 
corneal nerve parameters in the diagnosis of PDN.
It is acknowledged that this is a cross- sectional study and VAS is 
a subjective tool; however, this is a validated score to measure pain 
intensity in patients with PDN. Also skin biopsy to quantify IENFD 
or IENFL, a sensitive marker of small fibre neuropathy, was not per-
formed although as discussed earlier there is considerable debate 
regarding the association between IENFD and PDN. A significant 
proportion of patients were on medication for neuropathic pain, 
24 h prior to their assessment, which could have impacted on the 
assessment of the severity of neuropathic pain.
In conclusion, it is shown that CCM has good diagnostic accuracy 
for PDN and detects progressively greater small nerve fibre loss in 
F I G U R E  4  ROC curves for corneal 
nerve fibre density CNFD (no./mm2), 
corneal nerve branch density (CNBD, 
no./mm2) and corneal nerve fibre length 
(CNFL, mm/mm2) for painful diabetic 
neuropathy
CCM parameters AUC p value
Optimal 
threshold Sensitivity Specificity
CNFD (no./mm2) 0.78 <0.0001 23.69 0.73 0.72
CNBD (no./mm2) 0.75 <0.0001 51.04 0.66 0.66
CNFL (mm/mm2) 0.74 <0.0001 21.48 0.66 0.65
Abbreviations: AUC, area under the curve; CCM, corneal confocal microscopy; CNBD, corneal 
nerve branch density; CNFD, corneal nerve fibre density; CNFL, corneal nerve fibre length.
TA B L E  4  Diagnostic performance of 
corneal nerve fibre parameters for the 
diagnosis of painful diabetic neuropathy
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patients with increasing severity of PDN. CCM may have clinical util-
ity as a rapid and objective test for the assessment of PDN.
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